Journal of Pharmaceutical and Biomedical Analysis 2011-01-05

Determination of oxaceprol in rat plasma by LC-MS/MS and its application in a pharmacokinetic study.

Jifeng Gu, Nianzu Chen, Guoqiang Ding, Zhen Zhang

Index: J. Pharm. Biomed. Anal. 54(1) , 173-8, (2011)

Full Text: HTML

Abstract

A sensitive method for the quantification of oxaceprol in rat plasma using high-performance liquid chromatography-tandem mass spectrometry (LC-MS/MS) was developed. Sample pretreatment involved a simple protein precipitation by the addition of 60 μL of acetonitrile-methanol (1:2, v/v) to 20 μL plasma sample volume. Separation was achieved on a Dikma ODS-C18 (5 μm, 150 mm × 4.6mm) reversed-phase column at 40 °C with acetonitrile/0.1% formic acid-4mM ammonium acetate in water (35:65,v/v) at a flow rate of 0.6mL/min. Detection was performed using an electrospray ionization (ESI) operating in negative ion multiple reaction monitoring (MRM) mode by monitoring the ion transitions from m/z 172 → 130 (oxaceprol) and m/z 153 → 109 (protocatechuic acid, internal standard). The calibration curve of oxaceprol in plasma showed good linearity over the concentration range of 1.25-800 ng/mL. The limit of detection and limit of quantification were 0.400 ng/mL and 1.25 ng/mL, respectively. Intra- and inter-day precisions in all samples were within 15%. There was no matrix effect. The validated method was successfully applied to a preclinical pharmacokinetic study of oxaceprol in rats. After oral administration of 20mg/kg oxaceprol to rats, the main pharmacokinetic parameters T(max), C(max), T(1/2), V(z/F) and AUC(0-t) were 1.4h, 1.2 μg/mL, 2.3h, 19.7 L/kg and 3.4 mg h/L, respectively.Copyright © 2010 Elsevier B.V. All rights reserved.


Related Compounds

Related Articles:

Oxaceprol, an atypical inhibitor of inflammation, reduces leukocyte adherence in mouse antigen-induced arthritis.

2001-06-01

[Acta Orthop. Scand. 72(3) , 293-8, (2001)]

[Assessment of the placebo effect of symptomatic slow-acting anti-arthritics].

1998-02-07

[Presse Med. 27(5) , 211-4, (1998)]

Oxaceprol is a well-tolerated therapy for osteoarthritis with efficacy equivalent to diclofenac.

2000-01-01

[Clin. Rheumatol. 19(2) , 99-104, (2000)]

Oxaceprol--a randomised, placebo-controlled clinical study in osteoarthritis with a non-conventional non-steroidal anti-inflammatory drug.

2007-01-01

[Clin. Exp. Rheumatol. 25(1) , 29-34, (2007)]

Oxaceprol is as effective as diclofenac in the therapy of osteoarthritis of the knee and hip.

2012-10-01

[Clin. Rheumatol. 18(1) , 4-9, (1999)]

More Articles...